The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence

Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: The aim of this study was to investigate the diagnostic accuracy of 18F-FDG-PET/CT in osteosarcoma patients suspicious for disease recurrence after adequate surgical therapy. Methods: Inclusion criteria were: a) adequate surgical treatment for proven osteosarcoma and documented complete remission after therapy; b) 18F-FDG-PET/CT performed during follow-up for clinical/diagnostic suspicion of relapse; c) new surgical treatment with excision of the suspected lesions; d) histological validation of 18F-FDG-PET/CT findings. Thirty-seven patients matching all inclusion criteria were retrospectively enrolled (20 men and 17 female). Primary surgical treatment consists of resection (31 cases) or amputation (six cases). 18F-FDG-PET/CT performance was assessed with a per-patient and per-site evaluation of sensitivity, specificity, accuracy, positive predicting value (PPV), and negative predicting value (NPV). The sites of relapse were classified as local, lung, lymphnodes (LNs), and distant (other skeletal segments and/or distant soft tissue). The disease-free survival (DFS) and the overall survival (OS) after 18F-FDG PET/CT were evaluated. Results: 18F-FDG-PET/CT was positive in 89.2% (33/37) of patients. Local uptake only was observed in 35.1% patients (13/37); lung uptake only in 18.9% (7/37); distant uptake only in 2.7% (1/37) case; multiple sites of uptake in 32.4% (12/37). Histology resulted positive in 92% (34/37) of patients. A total of 51 pathologic lesions were evaluated (22 local relapse, 11 lung metastasis, 10 metastatic LNs, eight distant metastatic lesions). On a per-patient analysis 18F-FDG-PET/CT showed a sensitivity, specificity, accuracy, PPV, and NPV of 91%, 75%, 89%, 97%, 50%. On a per-site analysis the performance for local relapse was 96%, 100%, 97%, 100%, 93%, while for lung relapse detection was 80%, 100%, 92%, 100%, 88%. The mean follow-up after 18F-FDG-PET/CT was 21.5 months. At the last follow-up, 19% (7/37) of patients were death with disease, 38% (14/37) were alive with disease, and 43% (16/37) had no evidence of disease. Overall survival was 90% and 75% at 24 and 60 months, respectively. Conclusion: 18F-FDG-PET/CT showed valuable results for detecting recurrence(s) in osteosarcoma patients with suspicious of relapse after treatment, particularly in the detection of local relapse and lung metastasis.

Original languageEnglish
Pages (from-to)1712-1720
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume44
Issue number10
DOIs
Publication statusAccepted/In press - Apr 12 2017

Fingerprint

Fluorodeoxyglucose F18
Osteosarcoma
Recurrence
Lung
Therapeutics
Neoplasm Metastasis
Sensitivity and Specificity
Survival
Amputation
Disease-Free Survival
Histology

Keywords

  • F-FDG-PET/CT
  • Osteosarcoma
  • Osteosarcoma re-surgery
  • Osteosarcoma relapse

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Angelini, A., Ceci, F., Castellucci, P., Graziani, T., Polverari, G., Trovarelli, G., ... Ruggieri, P. (Accepted/In press). The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 44(10), 1712-1720. https://doi.org/10.1007/s00259-017-3698-0

The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. / Angelini, Andrea; Ceci, Francesco; Castellucci, Paolo; Graziani, Tiziano; Polverari, Giulia; Trovarelli, Giulia; Palmerini, Emanuela; Ferrari, Stefano; Fanti, Stefano; Ruggieri, Pietro.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, No. 10, 12.04.2017, p. 1712-1720.

Research output: Contribution to journalArticle

Angelini, A, Ceci, F, Castellucci, P, Graziani, T, Polverari, G, Trovarelli, G, Palmerini, E, Ferrari, S, Fanti, S & Ruggieri, P 2017, 'The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence', European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 10, pp. 1712-1720. https://doi.org/10.1007/s00259-017-3698-0
Angelini A, Ceci F, Castellucci P, Graziani T, Polverari G, Trovarelli G et al. The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. European Journal of Nuclear Medicine and Molecular Imaging. 2017 Apr 12;44(10):1712-1720. https://doi.org/10.1007/s00259-017-3698-0
Angelini, Andrea ; Ceci, Francesco ; Castellucci, Paolo ; Graziani, Tiziano ; Polverari, Giulia ; Trovarelli, Giulia ; Palmerini, Emanuela ; Ferrari, Stefano ; Fanti, Stefano ; Ruggieri, Pietro. / The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. In: European Journal of Nuclear Medicine and Molecular Imaging. 2017 ; Vol. 44, No. 10. pp. 1712-1720.
@article{174e677a88da4a029ceca84a14f48f7e,
title = "The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence",
abstract = "Aim: The aim of this study was to investigate the diagnostic accuracy of 18F-FDG-PET/CT in osteosarcoma patients suspicious for disease recurrence after adequate surgical therapy. Methods: Inclusion criteria were: a) adequate surgical treatment for proven osteosarcoma and documented complete remission after therapy; b) 18F-FDG-PET/CT performed during follow-up for clinical/diagnostic suspicion of relapse; c) new surgical treatment with excision of the suspected lesions; d) histological validation of 18F-FDG-PET/CT findings. Thirty-seven patients matching all inclusion criteria were retrospectively enrolled (20 men and 17 female). Primary surgical treatment consists of resection (31 cases) or amputation (six cases). 18F-FDG-PET/CT performance was assessed with a per-patient and per-site evaluation of sensitivity, specificity, accuracy, positive predicting value (PPV), and negative predicting value (NPV). The sites of relapse were classified as local, lung, lymphnodes (LNs), and distant (other skeletal segments and/or distant soft tissue). The disease-free survival (DFS) and the overall survival (OS) after 18F-FDG PET/CT were evaluated. Results: 18F-FDG-PET/CT was positive in 89.2{\%} (33/37) of patients. Local uptake only was observed in 35.1{\%} patients (13/37); lung uptake only in 18.9{\%} (7/37); distant uptake only in 2.7{\%} (1/37) case; multiple sites of uptake in 32.4{\%} (12/37). Histology resulted positive in 92{\%} (34/37) of patients. A total of 51 pathologic lesions were evaluated (22 local relapse, 11 lung metastasis, 10 metastatic LNs, eight distant metastatic lesions). On a per-patient analysis 18F-FDG-PET/CT showed a sensitivity, specificity, accuracy, PPV, and NPV of 91{\%}, 75{\%}, 89{\%}, 97{\%}, 50{\%}. On a per-site analysis the performance for local relapse was 96{\%}, 100{\%}, 97{\%}, 100{\%}, 93{\%}, while for lung relapse detection was 80{\%}, 100{\%}, 92{\%}, 100{\%}, 88{\%}. The mean follow-up after 18F-FDG-PET/CT was 21.5 months. At the last follow-up, 19{\%} (7/37) of patients were death with disease, 38{\%} (14/37) were alive with disease, and 43{\%} (16/37) had no evidence of disease. Overall survival was 90{\%} and 75{\%} at 24 and 60 months, respectively. Conclusion: 18F-FDG-PET/CT showed valuable results for detecting recurrence(s) in osteosarcoma patients with suspicious of relapse after treatment, particularly in the detection of local relapse and lung metastasis.",
keywords = "F-FDG-PET/CT, Osteosarcoma, Osteosarcoma re-surgery, Osteosarcoma relapse",
author = "Andrea Angelini and Francesco Ceci and Paolo Castellucci and Tiziano Graziani and Giulia Polverari and Giulia Trovarelli and Emanuela Palmerini and Stefano Ferrari and Stefano Fanti and Pietro Ruggieri",
year = "2017",
month = "4",
day = "12",
doi = "10.1007/s00259-017-3698-0",
language = "English",
volume = "44",
pages = "1712--1720",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "10",

}

TY - JOUR

T1 - The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence

AU - Angelini, Andrea

AU - Ceci, Francesco

AU - Castellucci, Paolo

AU - Graziani, Tiziano

AU - Polverari, Giulia

AU - Trovarelli, Giulia

AU - Palmerini, Emanuela

AU - Ferrari, Stefano

AU - Fanti, Stefano

AU - Ruggieri, Pietro

PY - 2017/4/12

Y1 - 2017/4/12

N2 - Aim: The aim of this study was to investigate the diagnostic accuracy of 18F-FDG-PET/CT in osteosarcoma patients suspicious for disease recurrence after adequate surgical therapy. Methods: Inclusion criteria were: a) adequate surgical treatment for proven osteosarcoma and documented complete remission after therapy; b) 18F-FDG-PET/CT performed during follow-up for clinical/diagnostic suspicion of relapse; c) new surgical treatment with excision of the suspected lesions; d) histological validation of 18F-FDG-PET/CT findings. Thirty-seven patients matching all inclusion criteria were retrospectively enrolled (20 men and 17 female). Primary surgical treatment consists of resection (31 cases) or amputation (six cases). 18F-FDG-PET/CT performance was assessed with a per-patient and per-site evaluation of sensitivity, specificity, accuracy, positive predicting value (PPV), and negative predicting value (NPV). The sites of relapse were classified as local, lung, lymphnodes (LNs), and distant (other skeletal segments and/or distant soft tissue). The disease-free survival (DFS) and the overall survival (OS) after 18F-FDG PET/CT were evaluated. Results: 18F-FDG-PET/CT was positive in 89.2% (33/37) of patients. Local uptake only was observed in 35.1% patients (13/37); lung uptake only in 18.9% (7/37); distant uptake only in 2.7% (1/37) case; multiple sites of uptake in 32.4% (12/37). Histology resulted positive in 92% (34/37) of patients. A total of 51 pathologic lesions were evaluated (22 local relapse, 11 lung metastasis, 10 metastatic LNs, eight distant metastatic lesions). On a per-patient analysis 18F-FDG-PET/CT showed a sensitivity, specificity, accuracy, PPV, and NPV of 91%, 75%, 89%, 97%, 50%. On a per-site analysis the performance for local relapse was 96%, 100%, 97%, 100%, 93%, while for lung relapse detection was 80%, 100%, 92%, 100%, 88%. The mean follow-up after 18F-FDG-PET/CT was 21.5 months. At the last follow-up, 19% (7/37) of patients were death with disease, 38% (14/37) were alive with disease, and 43% (16/37) had no evidence of disease. Overall survival was 90% and 75% at 24 and 60 months, respectively. Conclusion: 18F-FDG-PET/CT showed valuable results for detecting recurrence(s) in osteosarcoma patients with suspicious of relapse after treatment, particularly in the detection of local relapse and lung metastasis.

AB - Aim: The aim of this study was to investigate the diagnostic accuracy of 18F-FDG-PET/CT in osteosarcoma patients suspicious for disease recurrence after adequate surgical therapy. Methods: Inclusion criteria were: a) adequate surgical treatment for proven osteosarcoma and documented complete remission after therapy; b) 18F-FDG-PET/CT performed during follow-up for clinical/diagnostic suspicion of relapse; c) new surgical treatment with excision of the suspected lesions; d) histological validation of 18F-FDG-PET/CT findings. Thirty-seven patients matching all inclusion criteria were retrospectively enrolled (20 men and 17 female). Primary surgical treatment consists of resection (31 cases) or amputation (six cases). 18F-FDG-PET/CT performance was assessed with a per-patient and per-site evaluation of sensitivity, specificity, accuracy, positive predicting value (PPV), and negative predicting value (NPV). The sites of relapse were classified as local, lung, lymphnodes (LNs), and distant (other skeletal segments and/or distant soft tissue). The disease-free survival (DFS) and the overall survival (OS) after 18F-FDG PET/CT were evaluated. Results: 18F-FDG-PET/CT was positive in 89.2% (33/37) of patients. Local uptake only was observed in 35.1% patients (13/37); lung uptake only in 18.9% (7/37); distant uptake only in 2.7% (1/37) case; multiple sites of uptake in 32.4% (12/37). Histology resulted positive in 92% (34/37) of patients. A total of 51 pathologic lesions were evaluated (22 local relapse, 11 lung metastasis, 10 metastatic LNs, eight distant metastatic lesions). On a per-patient analysis 18F-FDG-PET/CT showed a sensitivity, specificity, accuracy, PPV, and NPV of 91%, 75%, 89%, 97%, 50%. On a per-site analysis the performance for local relapse was 96%, 100%, 97%, 100%, 93%, while for lung relapse detection was 80%, 100%, 92%, 100%, 88%. The mean follow-up after 18F-FDG-PET/CT was 21.5 months. At the last follow-up, 19% (7/37) of patients were death with disease, 38% (14/37) were alive with disease, and 43% (16/37) had no evidence of disease. Overall survival was 90% and 75% at 24 and 60 months, respectively. Conclusion: 18F-FDG-PET/CT showed valuable results for detecting recurrence(s) in osteosarcoma patients with suspicious of relapse after treatment, particularly in the detection of local relapse and lung metastasis.

KW - F-FDG-PET/CT

KW - Osteosarcoma

KW - Osteosarcoma re-surgery

KW - Osteosarcoma relapse

UR - http://www.scopus.com/inward/record.url?scp=85017431132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017431132&partnerID=8YFLogxK

U2 - 10.1007/s00259-017-3698-0

DO - 10.1007/s00259-017-3698-0

M3 - Article

AN - SCOPUS:85017431132

VL - 44

SP - 1712

EP - 1720

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 10

ER -